General
Preferred name
Siremadlin
Synonyms
NVP-HDM201 ()
HDM201 ()
HDM-201 ()
Siremadline ()
Siremadlina ()
Hdm 201 ()
NVP-HDM 201 ()
HDM201 BBA ()
SIREMADLIN SUCCINATE ()
P&D ID
PD101146
CAS
1448867-41-1
Tags
available
drug candidate
Drug indication
Liposarcoma
Haematological malignancy
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
1.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Compound Sets
10
Cayman Chemical Bioactives
38516
ChEMBL Drugs
CHEMBL3653256
CHEMBL5095424
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB16331
DrugMAP
DMVRTCW
EU-OPENSCREEN Bioactive Compound Library
EOS100262
MedChem Express Bioactive Compound Library
HY-18658
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
External IDs
21
Properties
(calculated by RDKit )
Molecular Weight
554.12
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
5
Aromatic Ring Count
4
cLogP
4.69
TPSA
104.37
Fraction CSP3
0.27
Chiral centers
1.0
Largest ring
6.0
QED
0.34
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
virtual
MOA
p53-HDM2 PPI inhibitor
p53-MDM2 PPI inhibitor
MDM inhibitor
Pathway
Apoptosis
Metabolic Enzyme/Protease
Target
E1/E2/E3 Enzyme
MDM-2/p53
Source data